vs
Side-by-side financial comparison of Precipio, Inc. (PRPO) and Relay Therapeutics, Inc. (RLAY). Click either name above to swap in a different company.
Relay Therapeutics, Inc. is the larger business by last-quarter revenue ($7.0M vs $6.8M, roughly 1.0× Precipio, Inc.). Precipio, Inc. produced more free cash flow last quarter ($291.0K vs $-235.9M).
Precipio, Inc. is a specialty diagnostic firm that develops and provides advanced oncology, genetic, and rare disease testing solutions. It primarily serves healthcare providers, clinical laboratories, and patients across the United States, with a core focus on enhancing diagnostic accuracy and improving patient health outcomes.
Relay Therapeutics is a clinical-stage biotechnology company focused on developing precision oncology therapies. It leverages advanced computational modeling of protein dynamics, paired with cutting-edge experimental biology, to design targeted medicines for previously intractable cancer types, serving global oncology care markets and patient populations.
PRPO vs RLAY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.8M | $7.0M |
| Net Profit | $526.0K | — |
| Gross Margin | 45.9% | — |
| Operating Margin | 7.9% | — |
| Net Margin | 7.7% | — |
| Revenue YoY | 28.4% | — |
| Net Profit YoY | 244.1% | — |
| EPS (diluted) | $0.36 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $6.8M | $7.0M | ||
| Q3 25 | $6.9M | $0 | ||
| Q2 25 | $5.6M | — | ||
| Q1 25 | $4.9M | $7.7M | ||
| Q4 24 | $5.3M | $0 | ||
| Q3 24 | $5.3M | $0 | ||
| Q2 24 | $4.5M | $0 | ||
| Q1 24 | $3.5M | $10.0M |
| Q4 25 | $526.0K | — | ||
| Q3 25 | $-79.0K | $-74.1M | ||
| Q2 25 | $74.0K | — | ||
| Q1 25 | $-884.0K | $-77.1M | ||
| Q4 24 | $-365.0K | — | ||
| Q3 24 | $-626.0K | $-88.1M | ||
| Q2 24 | $-1.2M | $-92.2M | ||
| Q1 24 | $-2.1M | $-81.4M |
| Q4 25 | 45.9% | — | ||
| Q3 25 | 43.6% | — | ||
| Q2 25 | 43.2% | — | ||
| Q1 25 | 43.6% | — | ||
| Q4 24 | 49.8% | — | ||
| Q3 24 | 43.1% | — | ||
| Q2 24 | 38.1% | — | ||
| Q1 24 | 26.5% | — |
| Q4 25 | 7.9% | — | ||
| Q3 25 | -0.9% | — | ||
| Q2 25 | -14.6% | — | ||
| Q1 25 | -17.5% | -1105.2% | ||
| Q4 24 | -6.3% | — | ||
| Q3 24 | -11.3% | — | ||
| Q2 24 | -26.8% | — | ||
| Q1 24 | -59.6% | -903.0% |
| Q4 25 | 7.7% | — | ||
| Q3 25 | -1.1% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | -18.0% | -1003.6% | ||
| Q4 24 | -6.9% | — | ||
| Q3 24 | -11.9% | — | ||
| Q2 24 | -27.1% | — | ||
| Q1 24 | -59.8% | -813.3% |
| Q4 25 | $0.36 | — | ||
| Q3 25 | $-0.05 | $-0.43 | ||
| Q2 25 | $0.05 | — | ||
| Q1 25 | $-0.59 | $-0.46 | ||
| Q4 24 | $-0.22 | — | ||
| Q3 24 | $-0.42 | $-0.63 | ||
| Q2 24 | $-0.83 | $-0.69 | ||
| Q1 24 | $-1.46 | $-0.62 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.7M | $84.0M |
| Total DebtLower is stronger | $83.0K | — |
| Stockholders' EquityBook value | $14.6M | $567.1M |
| Total Assets | $21.3M | $621.3M |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.7M | $84.0M | ||
| Q3 25 | $2.3M | $91.6M | ||
| Q2 25 | $1.1M | — | ||
| Q1 25 | $1.0M | $93.5M | ||
| Q4 24 | $1.4M | $124.3M | ||
| Q3 24 | $1.1M | $152.4M | ||
| Q2 24 | $1.3M | $134.1M | ||
| Q1 24 | $776.0K | $152.9M |
| Q4 25 | $83.0K | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $383.0K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $14.6M | $567.1M | ||
| Q3 25 | $13.7M | $607.7M | ||
| Q2 25 | $12.3M | — | ||
| Q1 25 | $11.7M | $721.1M | ||
| Q4 24 | $12.1M | $777.8M | ||
| Q3 24 | $11.9M | $838.9M | ||
| Q2 24 | $12.1M | $681.7M | ||
| Q1 24 | $12.8M | $745.8M |
| Q4 25 | $21.3M | $621.3M | ||
| Q3 25 | $21.2M | $670.0M | ||
| Q2 25 | $18.8M | — | ||
| Q1 25 | $17.8M | $799.4M | ||
| Q4 24 | $17.0M | $871.3M | ||
| Q3 24 | $17.0M | $930.1M | ||
| Q2 24 | $17.3M | $772.5M | ||
| Q1 24 | $16.6M | $841.4M |
| Q4 25 | 0.01× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.03× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $366.0K | $-235.5M |
| Free Cash FlowOCF − Capex | $291.0K | $-235.9M |
| FCF MarginFCF / Revenue | 4.3% | -3370.0% |
| Capex IntensityCapex / Revenue | 1.1% | 5.9% |
| Cash ConversionOCF / Net Profit | 0.70× | — |
| TTM Free Cash FlowTrailing 4 quarters | $359.0K | $-622.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $366.0K | $-235.5M | ||
| Q3 25 | $10.0K | $-62.1M | ||
| Q2 25 | $353.0K | — | ||
| Q1 25 | $-44.0K | $-73.2M | ||
| Q4 24 | $565.0K | $-249.1M | ||
| Q3 24 | $41.0K | $-75.1M | ||
| Q2 24 | $500.0K | $-65.8M | ||
| Q1 24 | $-667.0K | $-50.3M |
| Q4 25 | $291.0K | $-235.9M | ||
| Q3 25 | $-44.0K | $-62.1M | ||
| Q2 25 | $294.0K | — | ||
| Q1 25 | $-182.0K | $-73.6M | ||
| Q4 24 | — | $-251.1M | ||
| Q3 24 | $-68.0K | $-75.3M | ||
| Q2 24 | — | $-65.8M | ||
| Q1 24 | — | $-52.1M |
| Q4 25 | 4.3% | -3370.0% | ||
| Q3 25 | -0.6% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | -3.7% | -958.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.3% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -520.7% |
| Q4 25 | 1.1% | 5.9% | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 2.8% | 5.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.1% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 17.8% |
| Q4 25 | 0.70× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.77× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
